• Eltanexor (KPT-8602): XPO1 Inhibition for Cancer Research

  2026-06-19

  Eltanexor (KPT-8602) is a second-generation, oral XPO1 inhibitor with validated activity in hematological and solid tumor models. It enables targeted nuclear export blockade, achieves nanomolar cytotoxicity in leukemia and lymphoma lines, and demonstrates reduced toxicity compared to earlier agents.

• N3-kethoxal: Enabling Structural Insights into DNA–Protein I

  2026-06-19

  Explore how N3-kethoxal advances nucleic acid research as a membrane-permeable, azide-functionalized probe for selective guanine labeling. This article uniquely demonstrates its value in dissecting DNA–protein interactions within immunothrombosis, providing actionable insight for high-impact genomic assays.

• LARP1-Ribosome Interactions Redefine TOP mRNA Repression Mec

  2026-06-18

  This study reveals that LARP1 directly binds non-translating ribosomal subunits and TOP mRNAs, forming repressed complexes whose molecular architecture was previously unclear. Contrary to prior models, ribosome binding is not required for LARP1-mediated TOP mRNA repression or stabilization, refining our understanding of translational control in mammalian cells.

• Iptacopan (LNP023): Selective Factor B Inhibitor for Complem

  2026-06-18

  Iptacopan (LNP023) is a potent, orally available, reversible inhibitor of complement factor B, targeting the alternative pathway C3bBb convertase. Peer-reviewed studies confirm its efficacy in paroxysmal nocturnal hemoglobinuria (PNH) and animal models, with robust selectivity and favorable pharmacokinetics. APExBIO supplies validated Iptacopan for research applications.

• HLY78: A Targeted Modulator of the Wnt/β-Catenin Pathway

  2026-06-17

  HLY78 is a selective small-molecule activator of the Wnt/β-catenin pathway, acting by enhancing Axin-LRP6 interactions in a ligand-dependent manner. The compound has demonstrated efficacy in embryonic development models and is well-characterized for research applications involving hematopoietic stem cell marker induction. Its properties and limitations make it a valuable but specialized tool for Wnt pathway studies.

• Practical Use of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-y

  2026-06-17

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol addresses the need for a high-purity, reproducible sGC activator and HIF-1α inhibitor in apoptosis and cancer biology research, specifically for modulation of hypoxia signaling and tumor angiogenesis. This reagent is not suitable for clinical or diagnostic applications and is recommended only for well-controlled experimental workflows.

• Bleb Structures in LNP-mRNA Enhance Transfection Efficiency

  2026-06-16

  Cheng et al. demonstrate that the induction of mRNA-rich bleb structures in lipid nanoparticle (LNP) formulations, particularly via high-concentration sodium citrate buffers at pH 4, significantly boosts transfection potency. This approach enhances mRNA integrity, offering a new formulation strategy to improve LNP-mediated mRNA delivery for in vitro and in vivo applications.

• Erlotinib and SCUBE3: Guiding Translational EGFR Research

  2026-06-16

  This thought-leadership article explores the evolving landscape of EGFR-targeted cancer research, integrating mechanistic insights into Erlotinib’s action with emerging paradigms involving SCUBE3-driven oncogenic signaling and immune evasion. By blending actionable protocol parameters with a strategic perspective on translational workflows, it provides researchers with practical guidance for designing robust, reproducible experiments and positions APExBIO's Erlotinib as a critical tool for next-generation discoveries.

• Iptacopan (LNP023): Redefining Complement Pathway Research

  2026-06-15

  This thought-leadership article provides translational researchers with a strategic, mechanistic perspective on Iptacopan (LNP023), a next-generation oral complement factor B inhibitor. Integrating biological rationale, validated protocols, and clinical insights, it positions Iptacopan as a pivotal tool for both experimental and therapeutic advancements in alternative pathway-driven disease.

• Telmisartan in Cardiac Hypertrophy: Pathways, Protocols & Po

  2026-06-15

  This thought-leadership article explores the mechanistic rationale and translational strategy for employing Telmisartan as a research tool in cardiac hypertrophy and cardiovascular disease models. By integrating recent discoveries in necroptosis signaling and comparative pathway insights, we provide actionable guidance for translational researchers seeking to refine protocols and maximize the clinical relevance of their hypertension and cardiac remodeling studies. Special attention is given to the competitive landscape and future outlook for targeting angiotensin II and necroptosis axes in cardiovascular research.

• Glabridin-Gold(I) Complex 6d: Enhancing Antitumor Immunity v

  2026-06-14

  This article examines the development and mechanistic action of complex 6d—a novel glabridin-gold(I) agent—designed to enhance antitumor immunity by dual targeting thioredoxin reductase and MAPK signaling pathways. The study demonstrates that 6d synergistically modulates the tumor microenvironment, supporting dendritic cell maturation and reducing immunosuppressive cell populations, with implications for combination immunotherapy strategies.

• Scenario-Driven Reliability with 2X Taq PCR Master Mix (with

  2026-06-13

  This article addresses real-world challenges in PCR-based cell viability and neurodegeneration assays, emphasizing how the 2X Taq PCR Master Mix (with dye) (SKU K1034) offers robust, reproducible solutions. Drawing from validated protocols and literature, we explore why this Taq DNA polymerase master mix with dye is a dependable choice for biomedical researchers seeking efficiency and data integrity.

• Antipyrine in Translational CNS Research: Beyond Benchmarkin

  2026-06-12

  Explore the multifaceted role of Antipyrine in CNS research, emphasizing its unique value in translational workflows and blood-brain barrier assay optimization. This in-depth analysis offers advanced insight into 1,5-dimethyl-2-phenylpyrazol-3-one for pharmacokinetic and pain relief studies.

• GW 6471: Advancing PPARα Antagonist Applications in Metaboli

  2026-06-12

  GW 6471 from APExBIO enables precision dissection of PPARα-driven pathways, empowering metabolic disease modeling and environmental toxicity research with robust, reproducible workflows. The latest zebrafish studies highlight its unique value in rescuing hepatotoxic phenotypes induced by environmental contaminants, offering researchers powerful mechanistic insight.

• Structure–Activity Insights: Novel 3-DT Brassinosteroid Deri

  2026-06-11

  This study introduces a new series of 3-dehydroteasterone derivatives, engineered with 23,24-dinorcholanic side chains and C-22 benzoate groups, and rigorously evaluates their plant growth activity. The findings clarify how specific structural modifications influence bioassay outcomes, providing actionable knowledge for designing potent plant growth regulators and informing future brassinosteroid research.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page